Navigation Links
Neurocrine Biosciences Reports Second Quarter 2011 Results
Date:7/28/2011

o 2011 is due to a full period of revenue recognition under the collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH and GPR119 programs, respectively. The Company entered into both of these collaboration agreements in June of 2010.

During the second quarter of 2011, the Company recognized $8.6 million of revenue from amortization of up-front licensing fees and $2.9 million in revenue from internal and external research and development expense reimbursement under its Abbott and Boehringer Ingelheim collaboration agreements. This compares to revenue of $2.6 million from amortization of up-front license fees and $1.3 million resulting from internal and external research and development expense reimbursements during the second quarter of 2010.

Revenue recognized from amortization of up-front license fees under the Abbott and Boehringer Ingelheim agreements for the first half of 2011 was $17.0 million compared to $2.6 million in 2010. Sponsored research and development revenue was $6.2 million for the first six months of 2011, compared to $1.3 million for the first half of 2010.

During each of the three and six month periods ended June 30, 2011 and 2010, the Company recognized revenue of $0.7 million and $1.5 million, respectively, from amortization of up-front licensing fees under our collaboration agreement for indiplon with Dainippon Sumitomo Pharma Co. Ltd.

Research and development expenses increased to $8.2 million during the second quarter of 2011 compared to $7.3 million for the same period in 2010. For the six months ended June 30, 2011, research and development expenses were $15.5 million, compared to $14.9 million for the same period last year. The increase in research and development expenses is primarily due to increased personnel and scientific consulting costs. These costs were offset by lower external development costs related to elagolix, as a result of the transition of development work to Abbott.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
2. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
3. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
7. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
8. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Local veterinarian, Dr. ... Hospital are seeking candidates to participate in an investigational ... The ultimate goal of this study is to ... into one or two arthritically affected joints can help ... , Candidates for the current investigational study must be ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 “This kit has ... to screen from 0 to 150 ppb,” said Mark Tess, ... a significant benefit to plant owners and USDA-GIPSA inspection agencies ... other commodities. Testing can take place in a matter of ... can the plant test the feed and grain before accepting ...
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... , EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - ... treatment of multiple sclerosis (MS), today announced that the Company ... Award" at the 4th Annual Scrip Awards held in London, ... development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide ...
... http://www.myngle.com ), the global language platform, has just ... Europe Unlimited,s European Venture Summit,(EVS) ( http://www.e-unlimited.com/events/p200245/overview.asp ). ... is a showcase for the most promising Information ... from all over Europe to meet,and present themselves ...
... Mass., Dec. 11 Pressure BioSciences, Inc. (Nasdaq: ... International ("Omni") today announced that they have entered into ... the terms of the Agreement, the companies will: (1) ... information; (2) co-promote certain products at industry trade shows ...
Cached Biology Technology:BioMS Medical recognized at Scrip Awards 2008 2Myngle Best ICT Company at the European Ventures Summit 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5
(Date:9/1/2014)... adapted to a life without light. They emit echolocation sounds ... distance to obstacles or prey. In their brains, they have ... out by researchers at Technische Universitt Mnchen (TUM) has shown ... external factors. , Closer objects appear larger ... an object, the number of activated neurons in its brain ...
(Date:8/31/2014)... a fast and accurate tool to diagnose tuberculosis ... newly developed test (TAM-TB assay) is the first ... children. The test features excellent specificity, a similar ... of a blood test. The promising findings are ... in children, particularly in tuberculosis-endemic regions. , The ...
(Date:8/31/2014)... us, germs go after each other. But when viruses ... infected microbes: Sometimes viruses actually carry helpful genes that ... or better attack its own hosts. , Scientists have ... robotically destroy anything it recognized as invading viral genes. ... that one variety of the bacterial immune system known ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2New tuberculosis blood test in children is reliable and highly specific 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... A team of scientists led by Dr. Kuniya Abe ... one of the most comprehensive genome-wide experimental analyses of ... the April issue of the journal Genome Research. , ... generated from opposite DNA strands at the same locus. ...
... that glow in the dark, University of Houston researchers ... clock cycles. , Gregory M. Cahill, associate professor of ... fellow UH researcher who is now at the University ... titled "Light-dependent Development of Circadian Gene Expression in Transgenic ...
... approval to Mylan Technologies, Inc., for the first generic ... used to treat patients suffering from severe chronic pain ... to the skin, this patch technology delivers fentanyl, an ... body through the skin providing pain relief for up ...
Cached Biology News:Researchers rein in regulatory RNAs 2Glow-in-the-dark zebrafish at UH hold keys to biological clocks 2Glow-in-the-dark zebrafish at UH hold keys to biological clocks 3
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
... DNA sequencing is the experimental process ... DNA region. The automated DNA Sequencing is ... thermostable DNA polymerase, which allows cycle sequencing ... and detected in a capillary instrument controlled ...
... 192 ) The antibody is preadsorbed to remove ... antibody buffered aqueous glycerol solution A ... Mg 2+ and Ca 2+ ), pH ... BSA (IgG, protease free) and 0.05% sodium azide ...
... The Bio-Plex maintenance, calibration, ... a custom 96-well plate used ... and calibration procedures using the ... MCV plate is for use ...
Biology Products: